Adeno-associated virus (AAV) has emerged as a fundamental component in the gene
therapy landscape, widely acknowledged for its effectiveness in therapeutic gene delivery …

Over the past twenty years, ocular gene therapy has primarily focused on addressing
diseases linked to various genetic factors. The eye is an ideal candidate for gene therapy …

Purpose: Adeno-associated virus (AAV) demonstrates promise in delivering therapeutic
genes to retinal ganglion cells (RGCs). Delivery of neuroprotective genes is constrained by …

Age-related macular degeneration (AMD) is a leading cause of vision loss in the elderly,
significantly diminishing quality of life. Currently, there is no available treatment to reverse …

Abstract Introduction Alzheimer's Disease (AD), a progressive neurodegenerative disorder,
is marked by cognitive deterioration and heightened neuroinflammation. The influence of …

Adeno-associated virus (AAV) gene therapy vectors are an accepted platform for treating
severe neurological diseases. Test article (TA)-related and procedure-related …

Ocular gene therapy has rapidly advanced from proof-of-concept studies to clinical trials by
exploiting the unique advantages of the eye, including its easy accessibility, relative immune …

Inherited retinal diseases (IRDs) are a clinically and genetically diverse group of progressive
degenerative disorders that can result in severe visual impairment or complete blindness …

Age-related macular degeneration (AMD) is a prevalent retinal disorder that leads to central
vision loss, mainly due to chronic inflammation. Tumor necrosis factor-alpha (TNF-α) is a …

Ocular disorders remain a major global health challenge with unmet medical needs. RNA
nanomedicine has shown significant therapeutic benefits and safety profiles in patients with …